Nasus Pharma Appoints Nir Sassi as CFO
Nir Sassi’s appointment as chief financial officer took effect November 11, 2026. Nasus Pharma plans to begin its NS002 pivotal Phase 3 study in Q4 2026 and report topline data in Q1 2027.
Nir Sassi’s appointment as chief financial officer took effect November 11, 2026. Nasus Pharma plans to begin its NS002 pivotal Phase 3 study in Q4 2026 and report topline data in Q1 2027.